Moreover, the lysozyme treated group demonstrated immune tolerance by upregulating the expression of forkhead box P3 (FOXP3) and downregulating the pro-inflammatory molecules including IL-1β, cyclooxygenase-2 (COX-2), T-bet, and inhibitor of kappa light chain gene enhancer in B cells, alpha I-kappa-B-alpha (IκB-α), thereby exerting a preventive effect against DSS-induced colitis (137). This evidence concerns the gene LYZ and colitis.